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High serum alkaline phosphatase concentrations are
associated with elevated serum C-reactive protein (CRP)
levels in the general population. To examine whether this
association is independent of serum vitamin D levels or
modified in chronic kidney disease (CKD), we determined if
such associations exist using data from the National Health
and Nutrition Examination Survey III of 14,420 adult
participants in which 5.7% had CKD (defined as estimated
glomerular filtration rate o60ml/min per 1.73m2). For each
doubling of serum alkaline phosphatase, the odds of
elevated serum CRP (over 3mg/l) were increased 2.73-fold in
the non-chronic and 2.50-fold in the CKD sub-populations,
respectively. Regression coefficients of each doubling of
serum alkaline phosphatase with elevated CRP were not
significantly different in between the sub-populations.
Additional adjustment for the serum 25-hydroxy (OH) vitamin
D level did not substantively change the results. Thus,
associations of serum alkaline phosphatase with elevated
CRP are independent of serum 25-OH vitamin D in the
chronic and non-CKD populations. Hence, serum alkaline
phosphatase might be a marker of the inflammatory milieu.
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Alkaline phosphatase is primarily secreted by the liver and
the bone,1 although a small amount is as well secreted by
intestine, kidneys, and leukocytes. It is an indicator for bone
turnover, particularly in patients with chronic kidney disease
(CKD).1–2 Recent studies suggest that high serum alkaline
phosphatase levels predict mortality independent of bone
metabolism parameters and liver function tests in CKD3 and
chronic hemodialysis patients.4–6
A possible explanation for the above associations of serum
alkaline phosphatase with mortality in the CKD population is
inflammation. Elevated markers of inflammation, such as
serum C-reactive protein (CRP), are associated with
increased risk of cardiovascular disease and mortality in the
general and CKD populations.7–10 Studies in the general
population suggest that higher serum alkaline phosphatase is
associated with elevated serum CRP levels.11–12 However, this
association might be confounded by serum vitamin D levels
as lower vitamin D levels are associated with both elevated
serum CRP levels13 and elevated serum alkaline phosphatase
levels (resulting from increased osteoblastic activity).14
Therefore, we hypothesized that, in the CKD population,
high serum alkaline phosphatase levels might be associated
with elevated CRP and this association might in part
explained by low serum vitamin D levels. Hence, we
examined whether high serum alkaline phosphatase levels
are indeed associated with elevated serum CRP levels and if
this relationship can be attenuated or abolished by adjusting
for serum vitamin D levels, specifically in the CKD
population, using the National Health and Nutrition
Examination Survey (NHANES) III database. Furthermore,
we also examined whether the associations of serum alkaline
phosphatase levels with serum CRP levels differed by the
presence or absence of CKD.
RESULTS
Of the 15,837 adults (20 years or older) in NHANES III with
valid data (serum creatinine, age, sex, and race) for
glomerular filtration rate (GFR) estimation, 14,420 had
non-missing data for serum alkaline phosphatase, vitamin D,
CRP levels, and metabolic syndrome components. These
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participants were included in the current analysis. Of these,
5.7% had CKD.
Table 1 summarizes the clinical characteristics of the non-
CKD and CKD populations categorized by the median value
of serum alkaline phosphatase in the CKD sub-population.
In general, higher serum alkaline phosphatase levels were
associated with older age, greater prevalence of cardiovas-
cular conditions, and physical inactivity in both non-CKD
and CKD participants. Higher serum alkaline phosphatase
levels were also associated with modest but statistically
significant higher levels of serum aspartate amino transferase
(AST) and alanine amino transferase (ALT). Higher serum
alkaline phosphatase levels were significantly associated with
diabetes, higher fasting plasma glucose, and greater waist
circumference in the non-CKD population but not in CKD.
A higher prevalence of 25-hydroxy (OH) vitamin D
deficiency (o15 ng/ml) was observed with increasing alkaline
phosphatase levels in the non-CKD and CKD sub-popula-
tions (Figure 1). In separate logistic regression models, for
each doubling of serum alkaline phosphatase, the unadjusted
odds of low 25-OH vitamin D were increased by a factor 1.66
(95% confidence interval (CI) 1.38–2.01) in the non-CKD
and by a factor of 2.09 (95% CI 1.31–3.34) in the CKD sub-
populations, respectively. When adjusted for demographics,
comorbidities, waist circumference, physical inactivity, smok-
ing, serum calcium and phosphorous, AST, ALT, bilirubin,
estimated GFR, hemoglobin, and fasting glucose, these
associations were significant in the non-CKD population
(odds ratio 1.30, 95% CI 1.04–1.62) but not in the CKD
population (odds ratio 1.44, 95% CI 0.72–2.86 in CKD).
The detection threshold lower limit of the assay used to
measure CRP in NHANES III was 2.1 mg/l. The median
(interquartile range) for CRP distribution in the entire
cohort, non-CKD sub-population, and CKD sub-population
was 2.10 (2.10, 2.78), 2.10 (2.10, 2.58), and 2.10 (2.10, 6.92)
mg/l, respectively. Using the 25th, 50th, and 75th percentiles
of serum alkaline phosphatase in the CKD sub-population,
both CKD and non-CKD sub-populations were divided into
four groups. Figure 2 displays the prevalence of elevated CRP,
Table 1 | Baseline characteristicsa by serum alkaline phosphatase levelsb in the non-CKD and CKD populations
Non-CKD participants CKD participants
p90 IU/l 490 IU/l P-value p90 IU/l 490 IU/l P-value
Alkaline phosphatase (IU/l) 68±0.3 112±0.8 72±0.7 119±1.7
Demographics
Age (years) 42±0.4 47±0.5 o0.001 69±0.8 71±0.9 0.023
Gender (male) (%) 47 (46–48) 54 (52–55) o0.001 39 (33–44) 35 (29–41) 0.214
Race (African American) (%) 9.9 (8.7–11.3) 12.1 (10.7–13.5) 0.019 7.9 (6.2–9.9) 6.6 (4.8–8.9) 0.232
Clinical parameters
Myocardial infarction (%) 2.1 (1.7–2.5) 4.6 (3.8–5.7) o0.001 13.4 (10.0–17.8) 19.0 (13.6–25.8) 0.103
Stroke (%) 1.0 (0.7–1.2) 2.8 (2.2–3.7) o0.001 7.2 (5.3–9.7) 12.1 (9.1–15.9) 0.002
Congestive heart failure (%) 1.0 (0.8–1.3) 2.5 (1.8–3.3) o0.001 9.3 (6.6–13.0) 16.2 (12.3–21.1) 0.016
Diabetes mellitus (%) 4.6 (4.0–5.2) 11.2 (10.0–12.5) o0.001 19.4 (16.4–22.8) 24.2 (19.8–29.2) 0.109
Hypertension (%) 25 (23–27) 39 (36–42) o0.001 70 (65–75) 77 (70–82) 0.098
Waist circumference (inches) 35.1±0.1 37.4±0.1 o0.001 38.3±0.3 38.2±0.4 0.848
Physically inactive (%) 12 (10–14) 17 (15–19) o0.001 21 (16–27) 34 (29–40) o0.001
Non-smoker (%) 72 (70–74) 68 (65–71) 0.003 90 (86–93) 84 (79–88) 0.076
Serum calcium (mg/dl) 9.25±0.02 9.29±0.02 0.002 9.33±0.03 9.39±0.03 0.126
Serum phosphorus (mg/dl) 3.43±0.01 3.45±0.02 0.227 3.47±0.03 3.56±0.03 0.049
Serum aspartate transaminase (IU/l) 20.6±0.2 23.4±0.3 o0.001 20.8±0.5 21.6±0.4 0.261
Serum alanine transaminase (IU/l) 16.7±0.4 20.9±0.6 o0.001 13.3±0.6 15.0±0.6 0.040
Serum bilirubin (mg/dl) 0.63±0.01 0.60±0.01 0.027 0.58±0.02 0.55±0.01 0.165
Estimated glomerular filtration rate (ml/min per 1.73m2) 94.1±0.5 93.2±0.5 0.124 50.3±0.4 47.9±0.6 0.001
Serum vitamin D (ng/ml) 30.3±0.4 28.2±0.4 o0.001 28.8±0.6 26.4±0.7 0.011
Plasma fasting glucose (mg/dl) 94.8±0.3 101.8±0.8 o0.001 106.1±1.6 106.2±2.1 0.988
Hemoglobin (g/dl) 14.1±0.03 14.4±0.04 o0.001 13.7±0.07 13.6±0.10 0.533
Abbreviation: CKD, chronic kidney disease.
aPercentages shown as percent (95% confidence interval); continuous measures shown as mean±s.e.
bBoth CKD and non-CKD participants are divided into two groups by the median serum alkaline phosphatase level in the CKD group.
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Figure 1 |Prevalence of low serum 25-hydroxy (OH) vitamin D
levels by serum alkaline phosphatase groups in non-chronic
kidney disease (CKD) and CKD populations.
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defined as serum CRP level 43.0 mg/l, by serum alkaline
phosphatase and serum vitamin D levels in the non-CKD
and CKD sub-populations. In separate multivariable
models without adjustment for serum vitamin D levels, each
doubling of serum alkaline phosphatase was associated with
2.73-fold (95% CI 2.16–3.46) higher odds of elevated CRP in
the non-CKD group and 2.50-fold (95% CI 1.57–3.98) higher
odds of elevated CRP in the CKD group, respectively
(Figure 3). Additional adjustment for serum 25-OH vitamin D
level did not significantly change the results (Figure 3), suggesting
that serum vitamin D level has minimal effects on the association
between serum alkaline phosphatase level and elevated serum
CRP in the general population or those with CKD.
In order to examine whether the associations of serum
alkaline phosphatase with elevated CRP varies by the
presence or absence of CKD, two approaches were adopted.
In the first approach, an interaction term of serum alkaline
phosphatase with CKD was entered into the full model of
the entire cohort. This interaction term was nonsignificant
(P¼ 0.741). In the second approach, the regression coefficients
of each doubling of serum alkaline phosphatase with elevated
CRP in the non-CKD and CKD sub-populations were compared
and these were also not significantly different (P¼ 0.734).
The associations of serum alkaline phosphatase as a
categorical variable with elevated CRP are summarized in
Tables 2 and 3.
In sensitivity analyses, we performed an additional
analysis using data only from participants who had
g-glutamyl transpeptidase (GGT) measured to evaluate
further the hepatobiliary component of the association
between alkaline phosphatase and CRP. In separate multi-
variable models, the odds ratio of elevated CRP with each
doubling of serum alkaline phosphatase without adjusting for
GGT (but adjusted for all the covariates listed in Table 2) in
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Figure 2 |Prevalence of elevated serum C-reactive protein
(CRP) (43mg/l) by serum alkaline phosphatase groups and
serum 25-hydroxy vitamin D levels in non-chronic kidney
disease (CKD) and CKD populations.
Non-CKD
CKD
Odds of elevated C-reactive protein per doubling
of serum alkaline phosphatase
2.55
2.50
2.76
2.73
Without adjustment for
serum 25 OH vitamin D
Without adjustment for
serum 25 OH vitamin D
With adjustment for
serum 25 OH vitamin D
With adjustment for
serum 25 OH vitamin D
0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0
Figure 3 |Associations of serum alkaline phosphatase with
elevated serum C-reactive protein (43mg/l) in non-chronic
kidney disease (CKD) and CKD populations. All models were
adjusted for age, gender, race, myocardial infarction, stroke,
congestive heart failure, diabetes, hypertension, waist
circumference, exercise level, smoking, serum calcium, serum
phosphorus, aspartate amino transferase, alanine amino
transferase, bilirubin, glomerular filtration rate, serum
hemoglobin, and serum fasting glucose. 25-OH vitamin D,
25-hydroxy vitamin D.
Table 2 | Associations of serum alkaline phosphatase levels as
a categorical variablea with elevated serum CRP levels
(43mg/l) in non-CKD population in logistic regression
models without and with adjustment for serum vitamin D
levels
Model 1b Model 2c
Serum alkaline phosphatase group Odds 95% CI Odds 95% CI
p 75 IU/l 1.00 1.00
76–90 IU/l 1.49 1.26–1.74 1.50 1.28–1.75
91–111 IU/l 1.99 1.69–2.36 2.01 1.70–2.37
X112 IU/l 3.53 2.76–4.50 3.56 2.80–4.52
Abbreviations: CI, confidence interval; CKD, chronic kidney disease; CRP, C-reactive
protein.
aSerum alkaline phosphatase groups defined by serum alkaline phosphatase
quartiles in the CKD participants.
bModel 1. Adjusted for age, gender, race, myocardial infarction, stroke, congestive
heart failure, diabetes, hypertension, waist circumference, physical inactivity,
smoking, estimated glomerular filtration rate, hemoglobin, serum calcium,
phosphorus, aspartate transaminase, alanine transaminase, bilirubin, and fasting
glucose.
cModel 2. Adjusted for Model 1 variables and serum 25-hydroxy vitamin D level.
Table 3 | Associations of serum alkaline phosphatase levels as
a categorical variablea with elevated serum CRP levels
(43mg/l) in CKD population in logistic regression models
without and with adjustment for serum vitamin D levels
Model 1b Model 2c
Serum alkaline phosphatase group Odds 95% CI Odds 95% CI
p75 IU/l 1.00 1.00
76–90 IU/l 1.24 0.71–2.16 1.24 0.71–2.18
91–111 IU/l 1.93 1.26–2.94 1.97 1.28–3.01
X112 IU/l 2.52 1.44–4.43 2.59 1.47–4.57
Abbreviations: CI, confidence interval; CKD, chronic kidney disease; CRP, C-reactive
protein.
aSerum alkaline phosphatase groups defined by serum alkaline phosphatase
quartiles in the CKD participants.
bModel 1. Adjusted for age, gender, race, myocardial infarction, stroke, congestive
heart failure, diabetes, hypertension, waist circumference, physical inactivity,
smoking, estimated glomerular filtration rate, hemoglobin, serum calcium,
phosphorus, aspartate transaminase, alanine transaminase, bilirubin, and fasting
glucose.
cModel 2. Adjusted for Model 1 variables and serum 25-hydroxy vitamin D level.
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the non-CKD sub-population was 2.78 (95% CI 2.14–3.59)
and in the CKD sub-population was 2.64 (95% CI 1.47–4.74).
With further adjustment for GGT, the odds ratios for each
doubling of serum alkaline phosphatase with elevated
CRP remained statistically significant (in the non-CKD
sub-population 2.64 (95% CI 2.05–3.40) and CKD sub-
population 2.53 (95% CI 1.40–4.58).
DISCUSSION
Serum alkaline phosphatase levels are commonly elevated in
CKD and dialysis patients. The osteoblast is a prominent
source of alkaline phosphatase. As hyperparathyroidism and
high-turnover bone disease are common in dialysis patients,
an elevated serum alkaline phosphatase level is usually
considered as a marker of bone disease. However, the
potential role of alkaline phosphatase in the pathogenesis
of diseases has been increasingly recognized.
In CKD3 and chronic hemodialysis patients,4–6 high serum
alkaline phosphatase level was associated with increased
mortality. A potential mechanism for this increased mortality
is vascular calcification. Pyrophosphate in the arterial wall is
a potent inhibitor of vascular calcification. By hydrolyzing
pyrophosphate, alkaline phosphatase can promote vascular
calcification.15 Experimental support of a pathogenic role of
alkaline phosphatase in vascular calcification is as follows. In
calcified diabetic arteries, the expression of alkaline phos-
phatase is upregulated.15 The hydrolysis rate of pyropho-
sphate was increased in the aorta of uremic rats,16 which was
reduced by levamisole, a nonspecific inhibitor of alkaline
phosphatase. Although these studies support a role of
alkaline phosphatase in the arterial wall in the pathogenesis
of vascular calcification, the role of circulating alkaline
phosphatase is less clear. Nonetheless, higher levels of serum
alkaline phosphatase have been associated with progressive
arterial calcification in stage IV and V CKD patients.17
In addition to vascular calcification, there are other
potential mechanisms that may mediate the associations of
serum alkaline phosphatase with increased mortality. One of
the potential explanations is that higher serum alkaline
phosphatase might be associated with inflammation. In this
study, we examined whether serum alkaline phosphatase level
was associated with elevated serum CRP level.
As shown in Table 1, higher serum alkaline phosphatase
levels were associated with greater baseline prevalence of
cardiovascular disease and physical inactivity in both non-
CKD and CKD populations. In the non-CKD population,
higher serum alkaline phosphatase levels were also associated
with higher waist circumference and diabetes. These data
suggest that elevated serum alkaline phosphatase levels might
reflect not only altered bone mineral metabolism but also an
atherogenic milieu.
Atherosclerosis has been well established to be an
inflammatory process. In an earlier study of 1740 middle-
aged adults, compared with the normal alkaline phosphatase
group, serum alkaline phosphatase in the upper quartile was
associated with higher levels of serum CRP (2.58 vs 1.66 mg/l,
Po0.001).12 In another study of Chinese adults, higher
serum alkaline phosphatase levels were also associated
with elevated CRP levels.11 In an earlier analysis of the
Insulin Resistance Atherosclerosis Study cohort, compared
with the lowest quartile of serum alkaline phosphatase,
those in the highest quartile had a 2.3-fold higher odds
of developing incident metabolic syndrome subsequently.18
To our knowledge, whether elevated serum alkaline phos-
phatase is associated with elevated CRP has not been
examined in the CKD population. As shown in Figure 2,
higher serum levels of alkaline phosphatase were indeed
associated with greater prevalence of elevated serum CRP in
the CKD and non-CKD populations. As shown in Figure 3,
even after adjustment for other factors, in both CKD and
non-CKD populations, there was about a 2.5-fold increase
in the odds of elevated CRP with each doubling of serum
alkaline phosphatase. There was no evidence of effect
modification of this association by the presence or absence
of CKD.
Vitamin D deficiency, as reflected by low serum level of
25-OH vitamin D, is very prevalent. Vitamin D deficiency is
particularly prominent in CKD population. Lower levels of
serum vitamin D could be associated with both inflammatory
markers13 and elevated serum alkaline phosphatase14 levels.
Therefore, the associations of alkaline phosphatase with
inflammation could be confounded by serum 25-OH vitamin
D levels. We tested this hypothesis by examining the
associations of serum alkaline phosphatase with elevated
CRP, without and with adjusting for serum 25-OH vitamin D
levels. As shown in Tables 2 and 3 and Figure 3, adjustment
for serum 25-OH vitamin D levels had little effect on the
associations of serum alkaline phosphatase with elevated
serum CRP in both the non-CKD and CKD groups,
suggesting a 25-OH vitamin D independent association of
serum alkaline phosphatase with elevated CRP.
Finally, the associations of elevated serum alkaline
phosphatase with elevated serum CRP could reflect under-
lying liver disorder, such as non-alcoholic fatty liver disease.19
Although non-alcoholic fatty liver disease is the most
common cause for mild-to-moderate elevation in serum
AST and ALT, in about 70% of those with fatty liver, serum
AST, and ALT levels are normal.20 To attempt to characterize
this further, we conducted separate analyses in those
NHANES III participants who had GGT measured. Adjusting
for GGT had no significant effect on the odds of elevated
CRP. However, the presence of occult liver disease cannot be
definitively ruled out.
A major strength of this study is the careful data collection
in NHANES III, including the uniform measurements of
serum levels of alkaline phosphatase, serum 25-OH vitamin
D, and CRP. The major limitations of this study include those
that are usually present in all observational studies that use
existing databases. The observational nature of the study
limits inference beyond associations. Furthermore, as this
study is cross-sectional, the ability to deduce causality is
further limited. An additional limitation is that data on
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serum parathyroid hormone levels and bone-specific alkaline
phosphatase are not available in NHANES III.
In summary, this study shows that elevated serum alkaline
phosphatase levels in CKD and non-CKD are associated with
elevated serum CRP levels and this association is independent
of serum 25-OH vitamin D levels. Furthermore, elevated
serum alkaline phosphatase levels were also associated with
diabetes, hypertension, and cardiovascular disease. Thus,
serum alkaline phosphatase in CKD could reflect an
inflammatory and atherogenic milieu and not merely a
biomarker of bone mineral metabolism. These might be
potential mechanisms for the observed increased mortality
associated with elevated serum alkaline phosphatase seen in
CKD and hemodialysis patients.
MATERIALS AND METHODS
From 1988 to 1994, the National Center for Health Statistics
conducted NHANES III, a cross-sectional survey of the US
population. A complex, multistage sampling design was used to
allow results to be extrapolated to the entire non-institutionalized
civilian US population as of the early 1990s.21 Data on age, sex, race,
current or past cigarette smoking, and history of comorbid
conditions, such as myocardial infarction, stroke, and congestive
heart failure, were collected in a structured home interview
conducted by trained personnel. Diabetes was defined as the history
of diabetes or the use of insulin or oral diabetes medications or
fasting blood glucose X125 mg/dl. A detailed questionnaire on
leisure time physical activity was also administered during the home
interview. The home interview was followed by an examination by a
physician at a mobile examination center, which included blood
pressure measurement as well as extensive anthropometric,
physiological, and laboratory testing.
Serum specimens from collection sites were transported on dry
ice to the central laboratories and stored at 70 1C until analysis.
Serum biochemistry panel including serum alkaline phosphatase
was measured by a Hitachi 737 automated analyzer (Boehringer
Mannheim Diagnostics, Indianapolis, IN, USA). Serum 25-OH
vitamin D level was measured by a radioimmunoassay using the
25-OH D 125I radioimmunoassay kit (INCSTAR, Stillwater, MN, USA).
Serum CRP was measured by latex-enhanced nephelometry using a
Behring Nephelometer Analyzer System and reagents from Behring
Diagnostics, Somerville, NJ, USA.
Serum creatinine was measured using a kinetic-rate Jaffe method
in NHANES III. These serum creatinine measurements were
recalibrated to the creatinine standard provided by the Cleveland
Clinic Research Laboratory (Cleveland, OH, USA) using the equation
(0.184þ 0.960NHANES III measured serum creatinine in mg/dl).22
GFR was estimated as 175 (standardized serum creatinine)1.154
(age)0.203 0.742 (if the individual is woman) 1.212 (if the
individual is African American) ml/min per 1.73 m2 (ref. 23). CKD
was defined as GFR o60 ml/min per 1.73 m2.
A consensus statement of the Centers for Disease Control and the
American Heart Association categorized serum CRP level 43 mg/l
as high risk.24 Therefore, serum CRP 43 mg/l is defined as elevated
CRP in this study.
Data analysis
Several aspects of the NHANES design must be taken into account
in data analysis, including the sampling weights and the complex
survey design. We used the svy suite of commands in Stata 10 (Stata
10, College station, TX, USA) and followed the analytical guidelines
for NHANES data proposed by the Centers for Disease Control.21
It should be noted that the svy suite of commands in Stata use the
complex survey design of NHANES to calculate the expected means
and proportions of the entire US non-institutionalized civilian
population, and hence means and proportions are presented with
the estimated value and 95% CIs.
Association of serum alkaline phosphatase with serum vitamin
D level. As serum alkaline phosphatase levels were positively
skewed, these values were log transformed before statistical analyses.
The occurrence of a low serum 25 OH vitamin D level (defined as
o15 ng/ml) was related to serum alkaline phosphatase in separate
multivariable logistic regression analyses in the CKD and non-CKD
sub-populations. These analyses included covariates to adjust for
age, gender, race, history of myocardial infarction, stroke, congestive
heart failure, diabetes and hypertension, waist circumference,
physical inactivity, smoking, estimated GFR, hemoglobin, fasting
serum glucose, serum calcium, phosphorus, AST, ALT and bilirubin.
Association of serum alkaline phosphatase with serum CRP
level. The presence of inflammation, defined as serum CRP
43 mg/l, was related to serum alkaline phosphatase by fitting
separate multivariate logistic regression models in the non-CKD and
CKD sub-populations. The models included the following factors as
covariates: age, gender, race, history of myocardial infarction, stroke,
congestive heart failure, diabetes and hypertension, waist circum-
ference, physical inactivity, smoking, estimated GFR, hemoglobin,
fasting serum glucose, serum calcium, phosphorus, AST, ALT, and
bilirubin. Serum vitamin 25-OH vitamin D level was subsequently
added to each model as an additional covariate to examine whether
the association of serum alkaline phosphatase with elevated CRP is
independent of serum 25 OH vitamin D.
Two approaches were adopted to examine whether presence or
absence of CKD modified the association between CRP and serum
alkaline phosphatase. In the first approach, the logistic regression
coefficients relating elevated CRP to serum alkaline phosphatase were
first estimated in separate models for the CKD and non-CKD
populations. The coefficients for the two populations were compared
by computing the ratio of difference between the coefficients and the
square root of the sum of their squared standard errors, and then
relating this quantity to the standard normal distribution. In the
second approach, above logistic regression models were constructed
for the entire cohort (including CKD and non-CKD participants)
with the above covariates, and an interaction term of serum alklaline
phosphatase with CKD was entered into the model to test whether
this interaction term was significant.
To examine the association of serum alkaline phosphatase as a
categorical variable with serum CRP, both CKD and non-CKD sub-
populations were divided into four groups using the 25th, 50th, and 75th
percentiles of serum alkaline phosphatase in the CKD sub-population.
These groups were used in multivariable logistic regression models as
described above with the lowest alkaline phosphatase as the reference.
Sensitivity analyses
Serum GGT was added to the above covariates in the multivariable
logistic regression models for the subgroup of participants with
serum GGT measurements.
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